| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
16,774 |
15,468 |
$1.04M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
7,037 |
6,646 |
$314K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
6,799 |
1,981 |
$203K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,691 |
3,419 |
$184K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
5,929 |
1,786 |
$180K |
| 99215 |
Prolong outpt/office vis |
700 |
668 |
$78K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,098 |
1,073 |
$54K |
| 97032 |
|
4,238 |
1,506 |
$48K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
453 |
443 |
$48K |
| 64635 |
|
211 |
167 |
$48K |
| 64493 |
|
252 |
237 |
$35K |
| 97163 |
|
608 |
585 |
$34K |
| 64636 |
|
246 |
166 |
$34K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
3,889 |
3,263 |
$26K |
| 99205 |
Prolong outpt/office vis |
171 |
166 |
$23K |
| 64494 |
|
253 |
237 |
$20K |
| 97035 |
|
1,998 |
683 |
$17K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
319 |
300 |
$17K |
| 64495 |
|
131 |
123 |
$11K |
| 27096 |
|
88 |
83 |
$10K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
128 |
126 |
$10K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
102 |
100 |
$10K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
263 |
247 |
$7K |
| 99423 |
|
80 |
79 |
$6K |
| 64625 |
|
32 |
28 |
$6K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
19 |
17 |
$4K |
| 99201 |
|
61 |
60 |
$3K |
| 97162 |
|
59 |
58 |
$2K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
100 |
89 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
27 |
27 |
$2K |
| J1020 |
Injection, methylprednisolone acetate, 20 mg |
196 |
177 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
58 |
56 |
$1K |
| 99490 |
Ccm add 20min |
125 |
106 |
$1K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
26 |
23 |
$979.48 |
| 99422 |
|
21 |
20 |
$836.45 |
| 99421 |
|
18 |
18 |
$586.34 |
| 86328 |
|
13 |
13 |
$399.79 |
| G2212 |
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) |
18 |
17 |
$386.10 |
| 99406 |
|
28 |
27 |
$294.20 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
312 |
279 |
$269.45 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
41 |
40 |
$11.86 |
| 99072 |
|
116 |
108 |
$0.00 |